File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Bone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment.
Title | Bone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment. |
---|---|
Other Titles | Bone and Renal Safety Improvements in CHB Patients Switched to Tenofovir Alafenamide(TAF) after Tenofovir Disoproxil Fumarate(TDF) Treatment |
Authors | |
Issue Date | 2019 |
Citation | Liver Week, Korean Association for the Study of the Liver, Busan, Korea, 20-22 June 2019 How to Cite? |
Description | Free Paper Session 1 [HBV] - abstract no. 138 |
Persistent Identifier | http://hdl.handle.net/10722/272422 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WKW | - |
dc.date.accessioned | 2019-07-20T10:42:00Z | - |
dc.date.available | 2019-07-20T10:42:00Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Liver Week, Korean Association for the Study of the Liver, Busan, Korea, 20-22 June 2019 | - |
dc.identifier.uri | http://hdl.handle.net/10722/272422 | - |
dc.description | Free Paper Session 1 [HBV] - abstract no. 138 | - |
dc.language | eng | - |
dc.relation.ispartof | Liver Week, Korean Association for the Study of the Liver | - |
dc.title | Bone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment. | - |
dc.title.alternative | Bone and Renal Safety Improvements in CHB Patients Switched to Tenofovir Alafenamide(TAF) after Tenofovir Disoproxil Fumarate(TDF) Treatment | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.hkuros | 299507 | - |